Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07609719 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy

Name: A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy — clinical trial record (NCT07609719)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: OSSIA

StatusRecruiting

PhasePhase 4

SponsorGenentech, Inc.

Started2026-08-17

View on ClinicalTrials.gov ↗

The purpose of this study is to assess the imaging biomarkers, patient outcomes, safety, tolerability, and treatment satisfaction of ocrelizumab (OCR) combined with recombinant human hyaluronidase (rHuPH20) administered subcutaneously (SC) in participants with relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS) after switching from another anti-cluster of differentiation 20 (aCD20) therapy approved for RMS (ofatumumab SC, ublituximab-xiiy intravenous \[IV\], ocrelizumab IV) or PPMS (ocrelizumab IV).

Amendment history 2 changes detected by DataLookout

2026-08-14

Trial sites reduced: 11 → 1 locations

2026-07-30

Recruitment opened

Trial Details

NCT Number	NCT07609719
Lead Sponsor	Genentech, Inc.
Conditions	Multiple Sclerosis
Enrollment	100 participants
Start Date	2026-08-17
Primary Completion	2029-02-28 (estimated)
Study Completion	2029-02-28 (estimated)
Updated on ClinicalTrials.gov	2026-08-13